Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 2/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036880 | 0.95 | MAPT (0.43) | OGTCA1CA2MAPTSNCA | |
| SCHEMBL16419751 | 0.89 | KEAP1 (0.44) | CA1CA2CA12CA9MAPT | |
| SCHEMBL16419752 | 0.86 | CYP1B1 (0.45) | OGTCA1CA2CA12CA9 | |
| SCHEMBL15274991 | 0.85 | KEAP1 (0.49) | OGTMIFP2RY14 | |
| SCHEMBL15036892 | 0.83 | HSD17B1 (0.46) | CA1CA2CA12CA9MAPT | |
| SCHEMBL16419776 | 0.80 | CYP1B1 (0.47) | OGTMAPTSNCASQSTM1MIF | |
| SCHEMBL15036900 | 0.79 | KEAP1 (0.48) | OGTMAPTSNCAMIF | |
| SCHEMBL15036871 | 0.79 | OGT (0.43) | OGTMAPTSNCASQSTM1MIF | |
| SCHEMBL16603465 | 0.76 | KEAP1 (0.55) | P2RY14 | |
| SCHEMBL15274989 | 0.74 | CYP1B1 (0.56) | CA1CA2CA12CA9MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469616-B2 | Cyclic compounds and methods of making and using the same | CELLCEUTIX CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MUC1, TLR3, ALG1 | OGT 81/4885CA1 1067/4885CA2 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.